Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

Fouqueray, Pascale; Leverve, Xavier; Fontaine, Eric; Baquie, Mathurin; Wollheim, Claes; Lebovitz, Harold; Bozec, Sophie

doi:10.4172/2155-6156.1000126

Scientific article

English

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

ContributorsFouqueray, Pascale; Leverve, Xavier; Fontaine, Eric; Baquie, Mathurin; Wollheim, Claes; Lebovitz, Harold; Bozec, Sophie

Published inJournal of diabetes & metabolism, vol. 2, no. 4

Publication date2011

Affiliation entities

Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Citation (ISO format)

FOUQUERAY, Pascale et al. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. In: Journal of diabetes & metabolism, 2011, vol. 2, n° 4. doi: 10.4172/2155-6156.1000126

Article (Published version)

Identifiers

PID : unige:47301
DOI : 10.4172/2155-6156.1000126

Additional URL for this publicationhttp://www.omicsonline.org/2155-6156/2155-6156-2-126.digital/2155-6156-2-126.html

Journal ISSN2155-6156

944views

1downloads

Creation26/02/2015 15:59:00

First validation26/02/2015 15:59:00

Update time14/03/2023 22:55:56

Status update14/03/2023 22:55:56

Last indexation30/10/2024 23:08:13

Archive ouverte UNIGE

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

Technical informations